[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE283845T1 - Pyrimidinon verbindungen - Google Patents

Pyrimidinon verbindungen

Info

Publication number
ATE283845T1
ATE283845T1 AT00920741T AT00920741T ATE283845T1 AT E283845 T1 ATE283845 T1 AT E283845T1 AT 00920741 T AT00920741 T AT 00920741T AT 00920741 T AT00920741 T AT 00920741T AT E283845 T1 ATE283845 T1 AT E283845T1
Authority
AT
Austria
Prior art keywords
pyrimidinone compounds
pyrimidinone
compounds
Prior art date
Application number
AT00920741T
Other languages
English (en)
Inventor
Ashley Edward Fenwick
Deirdre Mary Bernadette Hickey
Robert John Ife
Colin Andrew Leach
Ivan Leo Pinto
Stephen Allan Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9910048A external-priority patent/GB9910048D0/en
Priority claimed from GB0002096A external-priority patent/GB0002096D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE283845T1 publication Critical patent/ATE283845T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00920741T 1999-05-01 2000-04-25 Pyrimidinon verbindungen ATE283845T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9910048A GB9910048D0 (en) 1999-05-01 1999-05-01 Novel compounds
GB0002096A GB0002096D0 (en) 2000-01-28 2000-01-28 Novel compounds
PCT/EP2000/003727 WO2000066567A1 (en) 1999-05-01 2000-04-25 Pyrimidinone compounds

Publications (1)

Publication Number Publication Date
ATE283845T1 true ATE283845T1 (de) 2004-12-15

Family

ID=26243514

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00920741T ATE283845T1 (de) 1999-05-01 2000-04-25 Pyrimidinon verbindungen
AT04077397T ATE432265T1 (de) 1999-05-01 2000-04-25 Pyrimidinon verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04077397T ATE432265T1 (de) 1999-05-01 2000-04-25 Pyrimidinon verbindungen

Country Status (29)

Country Link
US (2) US6953803B1 (de)
EP (2) EP1175408B1 (de)
JP (1) JP2002543190A (de)
KR (1) KR20020012200A (de)
CN (1) CN1286822C (de)
AR (1) AR023777A1 (de)
AT (2) ATE283845T1 (de)
AU (1) AU766003B2 (de)
BR (1) BR0010220A (de)
CA (1) CA2371671A1 (de)
CO (1) CO5170521A1 (de)
CZ (1) CZ20013904A3 (de)
DE (2) DE60016397T2 (de)
DK (1) DK1175408T3 (de)
ES (1) ES2233361T3 (de)
HK (1) HK1044757B (de)
HU (1) HUP0201122A3 (de)
IL (1) IL146210A0 (de)
MX (1) MXPA01011186A (de)
MY (1) MY136037A (de)
NO (1) NO20015329D0 (de)
NZ (1) NZ515137A (de)
PE (1) PE20010070A1 (de)
PL (1) PL351690A1 (de)
PT (1) PT1175408E (de)
SI (1) SI1175408T1 (de)
TR (1) TR200103216T2 (de)
UY (1) UY26132A1 (de)
WO (1) WO2000066567A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146210A0 (en) * 1999-05-01 2002-07-25 Smithkline Beecham Plc Pyrimidinone compounds
CN1179952C (zh) 2000-02-16 2004-12-15 史密斯克莱·比奇曼公司 作为ldl-pla2抑制剂的嘧啶-4-酮衍生物
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127139D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127143D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP1644353A1 (de) * 2003-07-02 2006-04-12 Bayer HealthCare AG Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten
WO2005113797A2 (en) 2004-04-16 2005-12-01 Glaxo Group Limited METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
DE102004061009A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
DE102004061006A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Benzylthio-1,2,4-triazin-5(2H)-one
CN1954826A (zh) * 2005-10-26 2007-05-02 上海生物芯片有限公司 银杏叶提取物在降低胆固醇方面的用途
EA200971050A1 (ru) 2007-05-11 2010-06-30 Томас Джефферсон Юниверсити Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
CN101687009A (zh) 2007-05-11 2010-03-31 宾夕法尼亚大学理事会 治疗皮肤溃疡的方法
AR081399A1 (es) * 2010-05-17 2012-08-29 Glaxo Group Ltd Proceso para preparar un compuesto de pirimidinona, compuestos intermediarios en dicho proceso y procesos para repararlos.
TW201307324A (zh) 2010-12-06 2013-02-16 Glaxo Group Ltd 化合物
CN104478812A (zh) * 2010-12-06 2015-04-01 葛兰素集团有限公司 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物
WO2012080497A2 (en) 2010-12-17 2012-06-21 Glaxo Group Limited Methods of treatment and prevention of eye diseases
WO2013000108A1 (zh) * 2011-06-27 2013-01-03 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
US9273054B2 (en) 2011-07-27 2016-03-01 Glaxo Group Limited Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors
AU2012289492B2 (en) 2011-07-27 2016-02-04 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1H)-one compounds use as Lp-PLA2 inhibitors
KR101650262B1 (ko) * 2011-11-11 2016-08-22 화이자 인코포레이티드 2-티오피리미딘온
EP2948456A4 (de) 2013-01-25 2016-09-14 Glaxosmithkline Ip Dev Ltd Bicyclische pyrimidonverbindungen als lp-pla2-hemmer
CA2899091A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Compounds
AU2014210259B2 (en) 2013-01-25 2016-11-03 Glaxosmithkline Intellectual Property Development Limited Compounds
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
US9552473B2 (en) 2014-05-14 2017-01-24 Microsoft Technology Licensing, Llc Claiming data from a virtual whiteboard
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN104840963B (zh) * 2015-05-26 2018-02-16 河北东康生物科技有限公司 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用
CN106008362B (zh) * 2016-05-24 2018-08-10 杰达维（上海）医药科技发展有限公司 一种嘧啶衍生物的制备方法
JP6545747B2 (ja) * 2017-05-09 2019-07-17 山田化学工業株式会社 色素化合物
AU2020379796C1 (en) 2019-11-09 2024-05-02 Shanghai SIMR Biotechnology Co., Ltd Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1582527A (en) * 1975-12-29 1981-01-07 Smith Kline French Lab Pyrimidone and thiopyrimidone derivatives
DE69816471T2 (de) * 1997-11-06 2004-05-27 Smithkline Beecham P.L.C., Brentford Pyrimidinon verbindungen und diese enthaltende pharmazeutische zusammenstellungen
US6559155B1 (en) 1998-08-21 2003-05-06 Smithkline Beecham P.L.C. Pyrimidinone derivatives for the treatment of atherosclerosis
IL146210A0 (en) * 1999-05-01 2002-07-25 Smithkline Beecham Plc Pyrimidinone compounds

Also Published As

Publication number Publication date
KR20020012200A (ko) 2002-02-15
US6953803B1 (en) 2005-10-11
CA2371671A1 (en) 2000-11-09
DE60016397T2 (de) 2005-12-01
IL146210A0 (en) 2002-07-25
ES2233361T3 (es) 2005-06-16
BR0010220A (pt) 2002-05-14
HUP0201122A3 (en) 2003-11-28
SI1175408T1 (en) 2005-04-30
PL351690A1 (en) 2003-06-02
HK1044757B (en) 2005-07-08
PT1175408E (pt) 2005-04-29
MY136037A (en) 2008-08-29
EP1175408B1 (de) 2004-12-01
CO5170521A1 (es) 2002-06-27
DK1175408T3 (da) 2005-04-11
CN1358175A (zh) 2002-07-10
UY26132A1 (es) 2000-12-29
EP1175408A1 (de) 2002-01-30
US7115616B2 (en) 2006-10-03
NZ515137A (en) 2003-10-31
NO20015329L (no) 2001-10-31
WO2000066567A1 (en) 2000-11-09
US20040167142A1 (en) 2004-08-26
EP1479671A1 (de) 2004-11-24
DE60016397D1 (de) 2005-01-05
JP2002543190A (ja) 2002-12-17
MXPA01011186A (es) 2002-08-12
ATE432265T1 (de) 2009-06-15
CN1286822C (zh) 2006-11-29
CZ20013904A3 (cs) 2002-04-17
AU4120300A (en) 2000-11-17
NO20015329D0 (no) 2001-10-31
AU766003B2 (en) 2003-10-09
DE60042286D1 (de) 2009-07-09
TR200103216T2 (tr) 2002-04-22
HUP0201122A2 (en) 2002-08-28
HK1044757A1 (en) 2002-11-01
AR023777A1 (es) 2002-09-04
PE20010070A1 (es) 2001-03-10
EP1479671B1 (de) 2009-05-27

Similar Documents

Publication Publication Date Title
ATE432265T1 (de) Pyrimidinon verbindungen
CY2015035I2 (el) Ενωσεις πυριμιδινης
DE60031682D1 (de) Antibakterielle verbindungen
NO20024127L (no) Pyrimidin-forbindelser
NO20015536D0 (no) FAP-aktiverte anti-tumor-forbindelser
DE60210782D1 (de) Glukokinase beeinflussende verbindungen
DE60021262D1 (de) Bizyklische heteroaromatische verbindungen als lh-agonisten
EE200200224A (et) Uudsed ühendid
ATE283049T1 (de) Antibakterielle verbindungen
ATE222893T1 (de) Triazinylaminostilben verbindungen
NO20021503D0 (no) Kinazolinoner
ATE405580T1 (de) Antithrombotische verbindungen
NO20014926L (no) Farmasöytiske forbindelser
ATE258921T1 (de) Aryl-annellierte azapolycyclische verbindungen
NO20013769D0 (no) Kalsilytiske forbindelser
NO20021502D0 (no) Kinazolinoner
DE60132607D1 (de) Bicyclische heteroaromatische verbindungen
NO20020466D0 (no) Kalsilytiske forbindelser
DE60035826D1 (de) Entfernungsmesser
DE60228478D1 (de) Aryl-annellierte azapolyzyklische verbindungen
NO20014262D0 (no) Tiazoloindolinon-forbindelser
ID29984A (id) Senyawa-senyawa bis-stirilbifenil
SE9901271D0 (sv) Novel compounds
SE9901118D0 (sv) Novel compounds
SE9901117D0 (sv) Novel compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1175408

Country of ref document: EP